Protracted febrile myalgia as a challenging manifestation of familial Mediterranean fever: case-based review
- 165 Downloads
Protracted febrile myalgia syndrome (PFMS) in familial Mediterranean fever (FMF) patients is a vasculitic condition characterized by severe myalgia, fever, abdominal pain, diarrhea, and arthralgia/arthritis episodes lasting 4–6 weeks. Symptoms typically resolve with corticosteroid treatment. However, in recent years, corticosteroid-resistant PFMS patients have been reported. We herein report five pediatric FMF patients complicated with PFMS. In addition, demographic findings, Mediterranean fever (MEFV) gene analysis, symptoms at disease onset, time interval between the diagnoses of FMF and PFMS, co-existent diseases, and treatment responses were evaluated. Resolution of all PFMS symptoms was accepted as complete response, while decreased symptoms without full recovery as partial response. We searched PubMed using the keywords ‘protracted febrile myalgia’ and ‘anakinra’, and reviewed the literature. There were three male and two female patients. Median age at the diagnosis of FMF was 6 (3–10) years. The time from diagnosis of FMF to the development of PFMS was changed from 0 to 8 (median: 2) years. All of the patients, except one, had homozygous M694V mutation. All patients were treated with corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) first. Two out of five patients were exhibited partial response, while others exhibited complete response. Patients with partial response to the conventional therapies were treated with anakinra, and achieved a great response after the first dose. Anti-interleukin-1 (IL-1) therapy may be a beneficial and a reasonable treatment option, when there is insufficient response to NSAID and corticosteroid therapies in pediatric PFMS patients.
KeywordsFamilial Mediterranean fever Protracted febrile myalgia syndrome Anakinra Corticosteroids
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest for any pharmaceutical companies.
Written informed consent was obtained from the patients and their parents for publication of this article.
- 1.Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1879–1885. https://doi.org/10.1002/1529-0131(199710)40:10%3C1879::AID-ART23%3E3.0.CO;2-M CrossRefGoogle Scholar
- 3.Mattit H, Joma M, Al-Cheikh S, El-Khateeb M, Medlej-Hashim M, Salem N, Delague V, Megarbane A (2006) Familial Mediterranean fever in the Syrian population: gene mutation frequencies, carrier rates and phenotype–genotype correlation. Eur J of Med Genet 49:481–486. https://doi.org/10.1016/j.ejmg.2006.03.002 CrossRefGoogle Scholar
- 6.Langevitz P, Zemer D, Livneh A, Shemer J, Pras M (1994) Protracted myalgia syndrome in patients with familial Mediterranean fever. J Rheumatol 21:1708–1709Google Scholar
- 8.Soylu A, Kasap B, Türkmen M, Saylam GS, Kavukçu S (2006) Febrile myalgia syndrome in familial Mediterranean fever. J Clin Rheumatol 12:93–96. https://doi.org/10.1097/01.rhu.0000208635.64537.10 CrossRefGoogle Scholar
- 12.Kaplan E, Mukamel M, Barash J, Brik R, Padeh S, Berkun Y, Uziel Y, Tauber T, Amir J, Harel L (2007) Protracted febrile myalgia in children and young adults with familial Mediterranean fever: analysis of 15 patients and suggested criteria for working diagnosis. Clin Exp Rheumatol 25:114–117Google Scholar